The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine
Open accessAbstract
Lasmiditan, a serotonin 5-HT1F receptor agonist, was effective for acute treatment of patients with migraine in a phase 3 double-blind randomized controlled study. The current study was designed to replicate these findings in a generalizable population of patients with migraine, including those with a cardiovascular medical history. This prospective, double-blind, phase 3 multicentre study randomly assigned patients with migraine with and without aura (1:1:1:1 ratio) to oral lasmiditan 200 mg, 100 mg, 50 mg, or placebo. Patients were instructed to dose at home within 4 h of onset of migraine attack of at least moderate intensity and not improving. The primary objective was to assess the proportion of patients’ headache pain-free and most bothersome symptom-free at 2 h post-dose for each dose of lasmiditan versus placebo (NCT02605174). Patients (n = 3005) were assigned and treated (n = 2583, safety population): 1938 lasmiditan (200 mg n = 528, 100 mg n = 532, and 50 mg n = 556 included in primary analysis) and 645 placebo (540 included in primary analysis). Most patients (79.2%) had ≥1 cardiovascular risk factor at baseline, in addition to migraine. Lasmiditan was associated with significantly more pain freedom at 2 h (lasmiditan 200 mg: 38.8%, odds ratio 2.3, 95% confidence interval 1.8–3.1, P < 0.001; 100 mg: 31.4%, odds ratio 1.7, 1.3–2.2, P < 0.001; 50 mg: 28.6%, odds ratio 1.5, 1.1–1.9, P = 0.003 versus placebo 21.3%) and freedom from most bothersome symptom at 2 h (lasmiditan 200 mg: 48.7%, odds ratio 1.9, 95% confidence interval 1.4–2.4, P < 0.001; 100 mg: 44.2%, odds ratio 1.6, 1.2–2.0, P < 0.001; 50 mg: 40.8%, odds ratio 1.4, 1.1–1.8, P = 0.009 versus placebo 33.5%). Treatment-emergent adverse events were reported in 253 of 649 (39.0%), 229 of 635 (36.1%), and 166 of 654 (25.4%) of patients on lasmiditan 200, 100, and 50 mg, respectively, versus 75 of 645 (11.6%) on placebo. Most adverse events were CNS-related and included dizziness, somnolence and paraesthesia. Lasmiditan was effective at 2 h post-dose for acute treatment of migraine at all oral doses tested. Efficacy and safety were consistent with the previous phase 3 study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vos, T., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32154-2 · Cited by 13,220
The International Classification of Headache Disorders, 3rd edition (beta version)
Headache Classification Committee of the International Headache Society (IHS) (2013) · Cephalalgia · doi:10.1177/0333102413485658 · Cited by 8,229
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
Kyu, H. H., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdela, J., Abdelalim, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32335-3 · Cited by 4,081
Hay, S. I., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32130-x · Cited by 2,083
Pathophysiology of migraine: a disorder of sensory processing
Goadsby, P. J., Holland, P. R., Martins-Oliveira, M., Hoffmann, J., Schankin, C., & Akerman, S. (2017) · Physiological Reviews · doi:10.1152/physrev.00034.2015 · Cited by 1,998
Self-citationMigraine — Current Understanding and Treatment
Goadsby, P. J., Lipton, R. B., & Ferrari, M. D. (2002) · New England Journal of Medicine · doi:10.1056/nejmra010917 · Cited by 1,918
Self-citationHippisley-Cox, J., Coupland, C., & Brindle, P. (2017) · BMJ · doi:10.1136/bmj.j2099 · Cited by 1,703
Ferrari, M. D., Roon, K. I., Lipton, R. B., & Goadsby, P. J. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06711-3 · Cited by 987
Self-citationMarmura, M. J., Silberstein, S. D., & Schwedt, T. J. (2015) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.12499 · Cited by 568
Dodick, D., Lipton, R. B., Martin, V., Papademetriou, V., Rosamond, W., MaassenVanDenBrink, A., Loutfi, H., Welch, K. M., Goadsby, P. J., Hahn, S., et al. (2004) · Headache: The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2004.04078.x · Cited by 351
Self-citationAcute Migraine Therapy: Do Doctors Understand What Patients With Migraine Want From Therapy?
Lipton, R. B., & Stewart, W. F. (1999) · Headache: The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.1999.00006.x · Cited by 351
Lipton, R. B., Stewart, W. F., Sawyer, J., & Edmeads, J. G. (2001) · Headache: The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2001.01156.x · Cited by 338
Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta‐Analysis
Cameron, C., Kelly, S., Hsieh, S., Murphy, M., Chen, L., Kotb, A., Peterson, J., Coyle, D., Skidmore, B., Gomes, T., et al. (2015) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.12601 · Cited by 326
Mahmoud, A. N., Mentias, A., Elgendy, A. Y., Qazi, A., Barakat, A. F., Saad, M., Mohsen, A., Abuzaid, A., Mansoor, H., Mojadidi, M. K., et al. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-020498 · Cited by 287
Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study
Kuca, B., Silberstein, S. D., Wietecha, L., Berg, P. H., Dozier, G., Lipton, R. B., on behalf of the COL MIG-301 Study Group, COL MIG-301 Study Group, Adams, M., Alftine, C., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000006641 · Cited by 270
Self-citationFärkkilä, M., Diener, H.-C., Géraud, G., Láinez, M., Schoenen, J., Harner, N., Pilgrim, A., & Reuter, U. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70047-9 · Cited by 186
Pfaffenrath, V., Cunin, G., Sjonell, G., & Prendergast, S. (1998) · Headache: The Journal of Head and Face Pain · doi:10.1046/j.1526-4610.1998.3803184.x · Cited by 184
Ferrari, M. D., Färkkilä, M., Reuter, U., Pilgrim, A., Davis, C., Krauss, M., Diener, H.-C., & for the European COL-144 Investigators (2010) · Cephalalgia · doi:10.1177/0333102410375512 · Cited by 167
Lipton, R. B., Buse, D. C., Serrano, D., Holland, S., & Reed, M. L. (2013) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.12154 · Cited by 164
Targeted 5-HT1F Therapies for Migraine
Vila‐Pueyo, M. (2018) · Neurotherapeutics · doi:10.1007/s13311-018-0615-6 · Cited by 120
Rubio‐Beltrán, E., Labastida‐Ramírez, A., Villalón, C. M., & MaassenVanDenBrink, A. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.01.005 · Cited by 118
Trends in the Ambulatory Management of Headache: Analysis of NAMCS and NHAMCS Data 1999–2010
Mafi, J. N., Edwards, S. T., Pedersen, N. P., Davis, R. B., McCarthy, E. P., & Landon, B. E. (2015) · Journal of General Internal Medicine · doi:10.1007/s11606-014-3107-3 · Cited by 80
Buse, D. C., Reed, M. L., Fanning, K. M., Kurth, T., & Lipton, R. B. (2016) · Headache The Journal of Head and Face Pain · doi:10.1111/head.12962 · Cited by 70
Lipton, R. B., Reed, M. L., Kurth, T., Fanning, K. M., & Buse, D. C. (2017) · Headache The Journal of Head and Face Pain · doi:10.1111/head.13179 · Cited by 61
Treatment-Emergent CNS Symptoms Following Triptan Therapy are Part of The Attack
Goadsby, P., Dodick, D., Almas, M., Diener, H., Tfelt‐Hansen, P. C., Lipton, R. B., & Parsons, B. (2007) · Cephalalgia · doi:10.1111/j.1468-2982.2007.01278.x · Cited by 46
Self-citationMolina, K. C., Fairman, K. A., & Sclar, D. A. (2018) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s151073 · Cited by 19
Cited by
Ashina, M. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1915327 · Cited by 816
Ailani, J., Burch, R. C., Robbins, M. S., & the Board of Directors of the American Headache Society (2021) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.14153 · Cited by 766
Diagnosis and management of migraine in ten steps
Eigenbrodt, A. K., Ashina, H., Khan, S., Diener, H.-C., Mitsikostas, D. D., Sinclair, A. J., Pozo-Rosich, P., Martelletti, P., Ducros, A., Lantéri-Minet, M., et al. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00509-5 · Cited by 594
Ferrari, M. D., Goadsby, P. J., Burstein, R., Kurth, T., Ayata, C., Charles, A., Ashina, M., van den Maagdenberg, A. M. J. M., & Dodick, D. W. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00328-4 · Cited by 500
Self-citationMigraine: integrated approaches to clinical management and emerging treatments
Ashina, M., Buse, D. C., Ashina, H., Pozo-Rosich, P., Peres, M. F. P., Lee, M. J., Terwindt, G. M., Halker Singh, R., Tassorelli, C., Do, T. P., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32342-4 · Cited by 305
Metadata
- Authors
- Goadsby, P. J., Wietecha, L. A., Dennehy, E. B., Kuca, B., Case, M. G., Aurora, S. K., & Gaul, C.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-05-27
- Volume
- 142
- Issue
- 7
- Pages
- 1894-1904
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2947247420
- Cited by
- 274
- References
- 28
- FWCI
- 28.82
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.